查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986861

孤兒藥市場規模、佔有率、趨勢和預測：按藥物類型、疾病類型、研發階段、暢銷藥物、分銷管道和地區分類，2026-2034年

Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2025年全球孤兒藥市場規模為2,610億美元。展望未來，IMARC Group預測，該市場將以9.47%的複合年成長率從2026年成長至2034年，到2034年達到5,892億美元。目前，北美是該市場的主要驅動力，佔35.5%的市場。孤兒藥市場佔有率的擴大得益於人​​們日益認知到罕見疾病是一項重大的公共衛生挑戰，基因組學、生物技術和精準醫療的進步，以及國內外衛生監管機構訂定的有利法規結構。

孤兒藥市場的發展主要得益於有利的法規環境和政府為促進罕見疾病治療方法研發所提供的獎勵。監管機構提供的獎勵包括市場獨佔權、稅額扣抵、費用減免和加快核准流程。這些獎勵顯著降低了製藥公司的財務風險，並促進了特定治療領域的創新。另一個主要促進因素是全球罕見病患疾病率的不斷上升，以及人們對罕見疾病認知的提高和診斷技術的進步。基因組學和個人化醫療的進步提高了罕見遺傳疾病的檢測和標靶化，從而推動了對孤兒藥的需求。

美國孤兒藥市場受多種因素驅動。罕見病患疾病率的不斷上升影響著大量美國人，凸顯了對特藥日益成長的需求。先進的基因篩檢和診斷技術能夠早期、準確地識別罕見疾病，從而擴大了目標患者群體。此外，孤兒病組織和病患小組的有效倡導提高了公眾對孤兒藥的認知度、資金籌措和患者獲取途徑。美國醫療保健體系中孤兒藥的高定價潛力以及積極的報銷政策也促進了市場成長。由於替代治療方法有限以及所治療疾病的嚴重，孤兒藥往往價格昂貴。 2025 年，美國食品藥物管理局(FDA) 授予 ilzabrutinib 孤兒藥資格，這是一種處於實驗階段的新型、先進的、口服可逆的布魯蛋白酪氨酸激酶(BTK) 抑製劑，用於治療兩種罕見疾病，包括高熱自體免疫溶血性貧血 (wAIHA) 和 IgG4 相關疾病 (IgG4-RD)。

孤兒藥市場趨勢：

罕見病患疾病率和公眾意識的提高

人們日益認知到罕見疾病是一項重大的公共衛生挑戰，這正在推動市場成長。據估計，到2024年，全球將有約3億人患有罕見疾病。除了盛行率上升之外，流行病學研究和病患登記系統的改進也讓我們對這些疾病有了更全面的了解。倡導團體、非營利組織和宣傳宣傳活動在教育醫療專業人員、政策制定者和公眾方面也發揮著至關重要的作用。公眾意識的提高促進了早期診斷和疾病管理的改善，同時也增加了對新治療方法的需求。各國政府和私人企業正在加大對罕見疾病研究的投入，而資料共用的加強也提高了開發平臺效率。

基因組學和精準醫學的進展

基因組學、生物技術和精準醫學領域的科技進步正在迅速改變罕見疾病的診斷和治療，從而改善孤兒藥市場的前景。基因測序、生物資訊學和個人化醫療調查方法正在促進更精準的診斷和個人化治療方案的製定，尤其適用於罕見且複雜的遺傳性疾病。這些技術透過將藥物作用機制與個別遺傳標記連結起來，縮短了藥物研發週期，提高了標靶治療的成功率。此外，伴隨診斷的出現正在改善患者篩選和監測，從而增強治療的有效性和安全性。生物製藥公司正擴大利用這些技術，開發針對少數但需求未被滿足的患者群體的新型生技藥品、基因療法和基於核糖核酸（RNA）的治療方法。 IMARC Group預測，到2033年，伴隨診斷市場規模將達223億美元。

有利的法規結構和政府獎勵

國內外衛生機構提供的有利法規結構正在推動孤兒藥市場的成長。世界各國提供各種獎勵，鼓勵製藥公司投資罕見疾病治療。這些獎勵通常包括市場獨佔權、臨床研究稅額扣抵、監管費用豁免、快速核准和津貼。這些措施顯著降低了孤兒藥研發的財務門檻，因為孤兒藥針對的是少數病患群體，商業性價值較低。這些監管支持增強了企業的信心，為開發和銷售針對弱勢患者群體的未滿足需求的治療方法創造了更穩定可靠的環境，並維持了市場的長期成長。此外，各國政府正為罕見疾病管理撥出專案預算，這進一步刺激了對孤兒藥的需求。例如，印度政府根據自然資源保護委員會（NRDC）的提案，宣布計劃設立國家罕見疾病基金（NFRD），目前正在等待衛生和家庭福利部（MoHFW）的等候核准，併計劃在2024-25和2025-26會計年度累計97.4億盧比。預計在2026-27和2027-28會計年度也將累計類似或略多的款項。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球孤兒藥市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 生物製藥
  • 非生物製藥

第7章 市場區隔：依疾病分類

  • 腫瘤學
  • 血液學
  • 神經病學
  • 循環系統
  • 其他

第8章 市場區隔：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第9章 市場區隔：依暢銷藥物分類

  • Revlimid
  • Rituxan
  • 科帕松
  • 奧普迪沃
  • Keytruda
  • Imbruvica
  • Avonex
  • 森西珀
  • Soliris
  • 其他

第10章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路商店
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Alexion Pharmaceuticals Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bayer AG
    • Daiichi Sankyo Company Limited
    • Genentech USA, Inc（F. Hoffmann-La Roche AG）
    • GSK plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceuticals USA, Inc
Product Code: SR112026A2382

The global orphan drugs market size was valued at USD 261.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 589.2 Billion by 2034, exhibiting a CAGR of 9.47% from 2026-2034. North America currently dominates the market with 35.5% of the market share. The orphan drugs market share is expanding, driven by the increasing knowledge of rare diseases as a major public health issue, technological advancements in genomics, biotech, and precision medicine, and favorable regulatory framework offered by different national and international health authorities.

The market for orphan drugs is largely driven by supportive regulatory environments and government incentives to foster the development of therapies for rare diseases. Regulators offer incentives such as market exclusivity, tax credits, lower fees, and accelerated approval procedures. These incentives greatly lower the cost of financial risk for pharmaceutical firms and stimulate innovation in specialized therapeutic areas. Another key driver is the increasing incidence of rare diseases worldwide, combined with increased awareness and enhanced diagnostic technology. Developments in genomics and personalized medicine are allowing for improved detection and targeting of rare genetic disorders, driving the demand for orphan drugs.

The orphan drugs market in the United States is driven by several factors. The growing incidence of rare diseases, impacting a huge number of Americans, highlights the expanding need for specialized medicines. Advanced genetic screening and diagnostic technologies are allowing for earlier and more precise identification of rare conditions, driving a larger addressable patient base. Additionally, effective advocacy by rare disease organizations and patient groups is enhancing awareness, funding, and patient access to orphan drugs. High price potential and positive reimbursement practices in the American healthcare infrastructure also favor expansion opportunities. Orphan drugs also tend to bear higher prices given scarce alternatives as well as due to the extremely serious nature of conditions they seek to treat. In 2025, the US Food and Drug Administration (FDA) has awarded orphan drug status to rilzabrutinib, an experimental, new, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, including warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).

ORPHAN DRUGS MARKET TRENDS:

Increasing Prevalence and Awareness About Rare Diseases

The increasing knowledge of rare diseases as a major public health issue is driving the growth of the market. In 2024, it was estimated that approximately 300 million billion around world lived with rare diseases. Increasing prevalence rates, combined with enhanced epidemiological studies and patient registries, are illuminating the scope of these disorders. Greater awareness through advocate groups, non-profit organizations, and public campaigns has also been important in bringing education to healthcare providers, policymakers, and the general public. Greater awareness not only improves earlier diagnosis and disease management but also improves demand for novel therapies. Governments and private companies are committing more resources to rare disease research, and enhanced data sharing is moving the development pipeline more efficiently.

Advancements in Genomics and Precision Medicine

Technological advancements in genomics, biotech, and precision medicine are transforming the diagnosis and management of rare diseases at a strong pace offering a favorable orphan drugs market outlook. Genomic sequencing, bioinformatics, and personalized medicine methodologies are facilitating more accurate diagnosis and individualized treatment plans, especially for rare and complex genetic disorders. These technologies have compressed the drug discovery process and improved the success rate of targeted therapies by correlating drug mechanisms with individual genetic markers. In addition, the emergence of companion diagnostics enables improved patient selection and monitoring, which improves treatment efficacy and safety. Biopharmaceutical firms are increasingly using these technologies to create new biologics, gene therapies, and ribonucleic acid (RNA)-based treatments for small patient populations with high unmet medical needs. The IMARC Group predicts that the companion diagnostics market is expected to reach USD 22.3 Billion by 2033.

Favorable Regulatory Frameworks and Government Incentives

The favorable regulatory framework offered by different national and international health authorities is impelling the orphan drugs market growth. Various countries around the world provide a wide range of incentives designed to encourage pharmaceutical firms to invest in rare disease treatments. These incentives generally range from market exclusivity, clinical research tax credits, regulatory fees waiver, expedited approvals, and grant dollars. These encourage significantly the reductions of the money hurdles involved with the research and development of these orphan drugs with small target numbers and little commercial value. This regulatory encouragement builds confidence and generates a more stable and secure setting for firms to create and market therapies for unmet and vulnerable patient segments, sustaining long-term market growth. Governments are also allocating budgets for managing rare diseases, which is further driving the need for orphan drugs. For instance, Union of India announced its plan to establish a National Fund for Rare Diseases (NFRD) and provision for ₹974 crore for FYs 2024-25 and 2025-26 as suggested by NRDC awaiting MoHFW clearance. Similarly, or slightly greater, fund amount shall be provisioned for 2026-27 and 2027-28.

ORPHAN DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Type :

  • Biological
  • Non-Biological

Biological holds 65.8% of the market share. It represents the largest segment, chiefly because of their success in treating the underlying pathophysiologic mechanisms of orphan diseases. It is generally developed from living organisms and comprise monoclonal antibodies, gene therapies, recombinant proteins, and cell-based medicines. Its potential to provide targeted, disease-modifying actions renders them very well adapted to intricate and genetically influenced diseases. As biotechnology and genomics advance, biologics are being developed more for an increasingly broad range of rare conditions, such as specific cancers, immunodeficiencies, and metabolic diseases. Their growing presence in the market is facilitated by the robust pipeline of biologic orphan drugs, as well as by favorable regulatory mechanisms like fast-track approval and orphan designation. Moreover, the premium pricing and longer development cycles associated with biologics are often justified by their therapeutic value, especially in cases where treatment alternatives are limited or non-existent.

Analysis by Disease Type :

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Oncology holds 36.6% of the market share. The oncology segment holds a dominant position in the orphan drugs space due to the prevalent incidence of uncommon cancers and the pressing demand for targeted therapy. Uncommon cancers, like particular forms of leukemia, sarcomas, and lymphomas, tend to have fewer or no viable treatments, fueling immense research and development efforts. Pharmaceutical firms are moving more and more towards these orphan oncology indications because of advantages provided under the orphan drug act, such as market protection and lower development expense. Molecular biological advancements and the use of immunotherapy have increasingly pushed the speed of development in personalized cancer care, such as monoclonal antibodies and checkpoint inhibitors. Also, the partnerships among academic institutions and biotech companies have resulted in the discovery of novel biomarkers and pathways for unusual cancer subtypes.

Analysis by Phase :

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Phase I of orphan drug development focuses on evaluating safety, dosage range, and pharmacokinetics in a small group of healthy volunteers or affected patients. This phase plays a critical role in laying the foundation for subsequent clinical trials. Although the patient population is typically small, which aligns with the nature of rare diseases, careful monitoring is required to assess tolerability and identify any adverse reactions.

Phase II trials for orphan drugs are designed to evaluate therapeutic efficacy and further assess safety in a larger cohort of patients who are affected by the rare disease under investigation. This phase is particularly crucial in the orphan drug landscape, as it provides initial evidence of the drug's clinical benefit, which can guide decision-making for Phase III trials.

Phase III is the most resource-intensive phase of orphan drug development, focused on confirming the drug's efficacy, monitoring side effects, and comparing its performance to existing treatments or placebos.

Phase IV, or post-marketing surveillance, focuses on monitoring the long-term safety, effectiveness, and overall impact of orphan drugs after they receive regulatory approval and enter the market.

Analysis by Top Selling Drugs :

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Other

Keytruda holds 15.7% of the market share. Keytruda (pembrolizumab) is one of the best-selling medicines, including in the orphan drugs market. It is a PD-1 inhibitor that has found widespread use in oncology, especially for rare cancers such as Merkel cell carcinoma and primary mediastinal large B-cell lymphoma. Keytruda's success in gaining orphan drug status in several indications reflects its therapeutic utility and effectiveness in the treatment of diseases with high unmet needs. Its extensive clinical value and positive results have made it a pillar of immunotherapy, with uses that tend to go beyond initial approval ranges through continued studies and trials. By providing a notable survival advantage in a number of uncommon oncological disorders, Keytruda has set the standard for precision medicine. Regulatory pressure and ongoing innovation in biomarker-led therapies are assisting it in growing its base in the rare disease environment, solidifying its position as a market leader in the orphan drug space.

Analysis by Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Hospital pharmacies hold 48.2% of the market share. Hospital pharmacies hold the biggest market share. Hospital pharmacies are also essential in the dispensing of orphan drugs, especially because of the specialized nature and administration needs of these treatments. Most orphan drugs are applied in the treatment of complicated, life-threatening, or uncommon diseases that need close medical monitoring, hence the most suitable place for them to be dispensed is the hospital. These medications usually entail complex dosing regimens, intravenous delivery, or patient monitoring for side effects, all of which are best conducted in a hospital setting. Furthermore, hospitals commonly engage in post-marketing research and clinical trials, providing them with direct access to recently approved orphan therapies. Due to the limited availability and high price of orphan drugs, hospital pharmacies also collaborate closely with healthcare payers and drug manufacturers in ensuring proper inventory management as well as reimbursement coordination.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 35.5%. North America represents the largest segment, driven by strong regulatory support, technological advancements, and a rising focus on rare disease treatment. The United States, in particular, leads the region due to the well-established framework under the Orphan Drug Act, which provides incentives such as tax credits, market exclusivity, and expedited review processes. These provisions have encouraged pharmaceutical companies to invest in niche areas that previously lacked commercial viability. The increasing prevalence of rare diseases, estimated to affect over 30 million people in the US, is also contributing to growing demand for targeted therapies. Another leading trend is the convergence of precision medicine and genomic technologies in orphan drug development. With better diagnostic capabilities, more patients are being correctly diagnosed, resulting in improved treatment target and personalized treatments. Also, partnerships among biotech companies, academic institutions, and government agencies are driving innovation and accelerating research pipelines.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ORPHAN DRUGS MARKET ANALYSIS

The United States hold 93.00% of the market share in North America. The United States experiences increasing orphan drug adoption due to growing investment in THE pharmaceutical sector, driving research into rare diseases. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. Pharmaceutical companies allocate substantial resources to develop therapies targeting conditions with limited treatment options. Regulatory incentives, including expedited approvals and market exclusivity, encourage innovation. Growing collaborations between biotechnology firms and research institutions further accelerate drug development. Rising healthcare expenditures support the availability of orphan drugs, improving accessibility for patients. Expanding clinical trials enhance treatment options, addressing unmet medical needs. Public and private funding initiatives boost research efforts, fostering drug innovation. Advancements in drug formulation improve efficacy and patient outcomes. Increased awareness among healthcare providers leads to early diagnosis and intervention, optimizing treatment success, and thereby driving the market for orphan drugs.

ASIA PACIFIC ORPHAN DRUGS MARKET ANALYSIS

Asia-Pacific witnesses expanding orphan drug adoption due to the increasing prevalence of cancer, prompting pharmaceutical companies to develop specialized treatments. According to the National Cancer Registry Programme, the estimated number of incident cases of cancer in India for the year 2022 was found to be 14,61,427. Rising incidence of rare malignancies creates demand for novel therapies addressing unmet medical needs. Advancements in medical technology enhance drug discovery, leading to more effective treatment options. Favorable regulatory policies streamline approval processes, accelerating drug availability. Growing investments in oncology research foster innovation, promoting targeted therapies. Expanding healthcare infrastructure improves access to specialized treatments, supporting patient outcomes. Expanding clinical research collaborations facilitate new drug development, enhancing treatment efficacy. Increasing healthcare spending strengthens access to high-cost orphan drugs, ensuring affordability. Personalized medicine advancements align with the development of precision therapies, benefiting patients with rare cancers and augmenting the need for orphan drugs.

EUROPE ORPHAN DRUGS MARKET ANALYSIS

Europe is experiencing increasing orphan drug adoption due to growing research and development activities, propelling advancements in rare disease treatment. According to Eurostat, in 2023, the EU spent €381 Billion on research and development; R&D expenditure as a percentage of GDP stood at 2.22% in 2023, compared with 2.08% in 2013. Rising investment in drug discovery is facilitating novel therapeutic innovations. Expanding partnerships between biotech firms and academic institutions are accelerating clinical trials for orphan drugs. Enhanced funding in genetic research is enabling personalized medicine breakthroughs. Adoption of advanced biopharmaceutical technologies is improving drug efficacy and patient outcomes. Streamlined regulatory frameworks support faster orphan drug approvals. Moreover, the development of specialized research centers is expediting orphan drug discovery. Expanding healthcare innovation hubs are fostering new treatment methodologies. Support for translational research is enabling swift transition from laboratory discoveries to clinical applications.

LATIN AMERICA ORPHAN DRUGS MARKET ANALYSIS

Latin America observes expanding orphan drugs adoption due to growing online stores, offering greater accessibility to specialized treatments. The shift toward digital healthcare platforms enhances drug availability, allowing patients to access medications conveniently. Rising internet penetration supports e-commerce growth, driving online pharmaceutical sales. Streamlined distribution channels reduce barriers to obtaining orphan drugs, improving affordability. Digital pharmacies facilitate direct patient engagement, enhancing treatment adherence. Expanding telemedicine services complement online sales, promoting seamless healthcare access. Increasing digital literacy strengthens consumer confidence in online healthcare solutions.

MIDDLE EAST AND AFRICA ORPHAN DRUGS MARKET ANALYSIS

Middle East and Africa witness increasing orphan drugs adoption due to growing healthcare infrastructure, enhancing treatment accessibility for rare diseases. According to the Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. Expanding medical facilities improve diagnosis and patient care, strengthening market penetration. Government investments in specialized healthcare services facilitate orphan drug availability. Advancements in hospital networks ensure efficient drug distribution, supporting patient needs. Regulatory developments streamline drug approvals, accelerating market entry. Rising medical research initiatives foster innovation, contributing to orphan drug development.

COMPETITIVE LANDSCAPE:

Market players in the orphan drugs space are increasingly making strategic partnerships and mergers and acquisitions (M&A) to improve their research pipelines and broaden their product offerings. Pharmaceutical and biotech firms are prioritizing novel drug development, especially in fields like gene therapy, immunotherapy, and rare oncology. A key trend is the increase in alliances between specialty biotech companies and large pharma companies that have more commercialization capabilities. Firms are also using regulatory incentives to speed up development and obtain market exclusivity. Many players are investing in new, high-tech innovation such as AI-powered drug discovery and precision medicine to make clinical trials more efficient, thereby driving the orphan drugs market demand. These activities demonstrate an innovation and competition-oriented environment towards fulfilling unmet medical requirements for rare diseases.

The report provides a comprehensive analysis of the competitive landscape in the orphan drugs market with detailed profiles of all major companies, including:

  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo Company Limited
  • Genentech USA, Inc (F. Hoffmann-La Roche AG)
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceuticals U.S.A., Inc

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the orphan drugs market?

2. What is the future outlook of orphan drugs market?

3. What are the key factors driving the orphan drugs market?

4. Which region accounts for the largest orphan drugs market share?

5. Which are the leading companies in the global orphan drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Orphan Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Biological
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Biological
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hematology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Phase

  • 8.1 Phase I
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Phase II
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Phase III
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Phase IV
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Top Selling Drugs

  • 9.1 Revlimid
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Rituxan
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Copaxone
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Opdivo
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Keytruda
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Imbruvica
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Avonex
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast
  • 9.8 Sensipar
    • 9.8.1 Market Trends
    • 9.8.2 Market Forecast
  • 9.9 Soliris
    • 9.9.1 Market Trends
    • 9.9.2 Market Forecast
  • 9.10 Others
    • 9.10.1 Market Trends
    • 9.10.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Stores
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Alexion Pharmaceuticals Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Amgen Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 AstraZeneca
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Bayer AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Daiichi Sankyo Company Limited
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Genentech USA, Inc (F. Hoffmann-La Roche AG)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 SWOT Analysis
    • 16.3.7 GSK plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co., Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis Pharmaceuticals Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Pfizer Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Sanofi S.A.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
      • 16.3.12.4 SWOT Analysis
    • 16.3.13 Takeda Pharmaceuticals U.S.A., Inc
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio
      • 16.3.13.3 Financials
      • 16.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Orphan Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Orphan Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Orphan Drugs Market: Breakup by Drug Type (in %), 2025
  • Figure 4: Global: Orphan Drugs Market: Breakup by Disease Type (in %), 2025
  • Figure 5: Global: Orphan Drugs Market: Breakup by Phase (in %), 2025
  • Figure 6: Global: Orphan Drugs Market: Breakup by Top Selling Drugs (in %), 2025
  • Figure 7: Global: Orphan Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Orphan Drugs Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Orphan Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: Orphan Drugs (Biological) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Orphan Drugs (Biological) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Orphan Drugs (Non-Biological) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Orphan Drugs (Non-Biological) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Orphan Drugs (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Orphan Drugs (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Orphan Drugs (Hematology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Orphan Drugs (Hematology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Orphan Drugs (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Orphan Drugs (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Orphan Drugs (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Orphan Drugs (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Orphan Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Orphan Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Orphan Drugs (Phase I) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Orphan Drugs (Phase I) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Orphan Drugs (Phase II) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Orphan Drugs (Phase II) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Orphan Drugs (Phase III) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Orphan Drugs (Phase III) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Orphan Drugs (Phase IV) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Orphan Drugs (Phase IV) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Orphan Drugs (Revlimid) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Orphan Drugs (Revlimid) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Orphan Drugs (Rituxan) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Orphan Drugs (Rituxan) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Orphan Drugs (Copaxone) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Orphan Drugs (Copaxone) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Orphan Drugs (Opdivo) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Orphan Drugs (Opdivo) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Orphan Drugs (Keytruda) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Orphan Drugs (Keytruda) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Orphan Drugs (Imbruvica) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Orphan Drugs (Imbruvica) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Orphan Drugs (Avonex) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Orphan Drugs (Avonex) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Orphan Drugs (Sensipar) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Orphan Drugs (Sensipar) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Orphan Drugs (Soliris) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Orphan Drugs (Soliris) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Global: Orphan Drugs (Other Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Global: Orphan Drugs (Other Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Global: Orphan Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Global: Orphan Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Global: Orphan Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Global: Orphan Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Global: Orphan Drugs (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Global: Orphan Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Global: Orphan Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Global: Orphan Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: North America: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: North America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: United States: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: United States: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Canada: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Canada: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Asia Pacific: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Asia Pacific: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: China: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: China: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Japan: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Japan: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: India: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: India: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: South Korea: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: South Korea: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Australia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Australia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Indonesia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Indonesia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Europe: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Europe: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Germany: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Germany: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: France: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: France: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: United Kingdom: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: United Kingdom: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Italy: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Italy: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Spain: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Spain: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Russia: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Russia: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 98: Latin America: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 99: Latin America: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 100: Brazil: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 101: Brazil: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 102: Mexico: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 103: Mexico: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 104: Others: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 105: Others: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 106: Middle East and Africa: Orphan Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 107: Middle East and Africa: Orphan Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 108: Global: Orphan Drugs Industry: SWOT Analysis
  • Figure 109: Global: Orphan Drugs Industry: Value Chain Analysis
  • Figure 110: Global: Orphan Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Orphan Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Orphan Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Orphan Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Orphan Drugs Market Forecast: Breakup by Phase (in Million USD), 2026-2034
  • Table 5: Global: Orphan Drugs Market Forecast: Breakup by Top Selling Drugs (in Million USD), 2026-2034
  • Table 6: Global: Orphan Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 7: Global: Orphan Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Orphan Drugs Market Structure
  • Table 9: Global: Orphan Drugs Market: Key Players